Patent protection to Vegovi is expected to be at least twice efficiently, which contains an active ingredient of Nordisk, has an active ingredient GLP-1.
Michael Siluk | UCG | Getty images
Novo nordisk said Thursday, his weight loss drugs, who could get an expanded approval from US Food and Drug Administration within six months.
Chief Financial Officer Karken MAND Knudsen said that the Danish pharmaceutical company has received a priority in the application for treatment to reduce the mortal risk of the Danish pharmaceutical company.
The lighting of the health agency can significantly increase the prospects for the insurance coverage of highly valued drugs.
“I would say today, and fewer than six months and less than six months,” said CNBC’s Tatelbaum “street signs”.
Before, Novo Nordisk, the third quarterly revenues planned to expand the FDA, but declared no time schedules. He also informed about success and trade in the backs of the drug.
Healthy health
In August, evening test data showed vegovi reduced risk Basic cardiovascular events such as heart attacks or stroke compared to placebo.
“Second studies have obese obesity, we reduce the risk of cardiovascular?
Carefully considered results »Select“Law was for the Army for Novo-Norinsk’s Imposis”A medicine for reply»
The results gave additional strength to the company’s shares over this year. The shares were held before 5%, on Thursday, the morning; To date, the shares are about 45%.
According to Knudsen, the company offers a full copy of test results within about 10 days, and then the FDA will be six months to present his verdict.
According to him, approval said he would strengthen the possibilities of insurance companies that expand the use of medicines and pay for treatment. Some insurers have been reluctant to cover medicines so far – the US price is $ 1.350 per month – only for weight loss purposes.
“Prices for products are also a reflection of value transfers to society,” said Knuden.
“So how many data we are, it is cardiovascular disease or chronic kidney diseases or other commiples, which will create part of the total values when we discuss with payers and insurers.
However, both approval and delivery deficit can interfere with the drug. Knudsen Thursday, the company will continue to increase production.
“I can promise to come to you next year, we zoom so much,” he said.
